ZA200907251B - Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease - Google Patents

Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease

Info

Publication number
ZA200907251B
ZA200907251B ZA2009/07251A ZA200907251A ZA200907251B ZA 200907251 B ZA200907251 B ZA 200907251B ZA 2009/07251 A ZA2009/07251 A ZA 2009/07251A ZA 200907251 A ZA200907251 A ZA 200907251A ZA 200907251 B ZA200907251 B ZA 200907251B
Authority
ZA
South Africa
Prior art keywords
oxidopyridin
cyclopropylmethoxy
carboxamide
parkinson
dichloro
Prior art date
Application number
ZA2009/07251A
Other languages
English (en)
Inventor
Christine Ravinet-Trillou
Gilles Poughon
Christine Menet
Claire% Delgorge
Philippe Delay-Goyet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA200907251B publication Critical patent/ZA200907251B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA2009/07251A 2007-04-19 2009-10-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease ZA200907251B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
ZA200907251B true ZA200907251B (en) 2011-04-28

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/07251A ZA200907251B (en) 2007-04-19 2009-10-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR20150004885A (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015006807A (es) * 2012-11-28 2016-01-14 Sanofi Sa Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
CN122055155A (zh) * 2023-10-12 2026-05-15 美德阿利克斯株式会社 经皮吸收组合物
CN122421966A (zh) * 2023-10-12 2026-07-17 傲拓神经科学公司 用替伐普兰治疗神经精神病症

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ZA945609B (en) * 1993-07-28 1995-05-12 Rhone Poulenc Rorer Ltd [Di(ether or thioether)heteroaryl or fluoro substituted aryl] compounds
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
DE60018470T2 (de) * 1999-12-23 2006-02-16 Icos Corp., Bothell Cyclische amp spezifische phosphodiesterase inhibitoren
US20030069169A1 (en) * 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
US20060004056A1 (en) * 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
NZ542670A (en) * 2003-03-12 2008-11-28 Celgene Corp N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
US20070049611A1 (en) * 2005-06-10 2007-03-01 Talamas Francisco X Phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
US20100130554A1 (en) 2010-05-27
NZ580482A (en) 2011-10-28
AU2008257322A1 (en) 2008-12-04
MY148092A (en) 2013-02-28
ES2367408T3 (es) 2011-11-03
ATE513548T1 (de) 2011-07-15
ME00935B (me) 2012-06-20
SI2146714T1 (sl) 2011-10-28
TW200911247A (en) 2009-03-16
HRP20110666T1 (hr) 2011-10-31
PL2146714T3 (pl) 2011-10-31
EP2146714A1 (fr) 2010-01-27
MX2009011284A (es) 2009-11-02
CN101663035A (zh) 2010-03-03
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
IL201448A (en) 2014-08-31
CL2008001136A1 (es) 2009-01-16
EA200970970A1 (ru) 2010-02-26
PA8776801A1 (es) 2008-11-19
FR2915100A1 (fr) 2008-10-24
MA31367B1 (fr) 2010-05-03
IL201448A0 (en) 2010-05-31
KR20150004885A (ko) 2015-01-13
KR20090130059A (ko) 2009-12-17
CN101663035B (zh) 2012-06-20
TWI439269B (zh) 2014-06-01
KR101503942B1 (ko) 2015-03-18
JO2678B1 (en) 2013-03-03
UY31035A1 (es) 2008-11-28
WO2008145841A1 (fr) 2008-12-04
CA2684174C (fr) 2014-02-25
RS51869B (sr) 2012-02-29
FR2915100B1 (fr) 2009-06-05
JP5386478B2 (ja) 2014-01-15
PT2146714E (pt) 2011-09-02
EA019194B1 (ru) 2014-01-30
CA2684174A1 (fr) 2008-12-04
HK1141725A1 (en) 2010-11-19
CY1111840T1 (el) 2015-10-07
AU2008257322B2 (en) 2013-06-13
AR066108A1 (es) 2009-07-22
EP2146714B1 (fr) 2011-06-22
JP2010524906A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
ZA200909191B (en) Catecholamine derivatives useful for the treatment of parkinson's disease
ZA201002751B (en) Compositions for treating parkinson's disease
ZA200805839B (en) Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
IL213259A0 (en) Composition for the use to treat alzheimer's disease
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
HUE043807T2 (hu) GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
PL2229369T3 (pl) Pochodne 6,7-dialkoksychinazoliny użyteczne do leczenia zaburzeń związanych z rakiem
AU2008233088A8 (en) Calcimimetic compounds for use in the treatment of bowel disorders
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL206107A0 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
IL201448A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of motor disorders related to parkinson's disease
IL201451A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of spinal cord traumas
EP2214488A4 (en) COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE AND RELATED DISORDERS
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL201447A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of cranial traumas
IL194275A0 (en) Use of digitalis-like compounds in the treatment of affective disorders
GB0700210D0 (en) The treatment of fibrotic disorders
GB0703787D0 (en) The treatment of fibrotic disorders
HK1147194A (en) Compositions for treating parkinson's disease
GB0724947D0 (en) Composition for the treatment of psychiatric disorders